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Abstract
Introduction: Regulatory factor X-box 1 (RFX1) can interact with DNA methyltransferase 1 (DNMT1) and histone
deacetylase 1 (HDAC1), and RFX1 down-regulation contributes to DNA hypomethylation and histone H3
hyperacetylation at the cluster of differentiation (CD) 11a and CD70 promoters in CD4
+ T cells of patients with
systemic lupus erythematosus (SLE). This leads to CD11a and CD70 overexpression, thereby triggering autoimmune
responses. In order to provide more insight into the epigenetic mechanisms leading to the deregulation of
autoimmune-related genes in SLE, we asked whether RFX1 is involved in regulating histone 3 lysine 9 (H3K9) tri-
methylation at the CD11a and CD70 promoters in SLE CD4
+ T cells.
Methods: CD4
+ T cell samples were isolated from 15 SLE patients and 15 healthy controls. H3K9 tri-methylation
levels were measured by chromatin immunoprecipitation (ChIP) and real-time quantitative PCR. CD4
+ T cells were
transfected with plasmids using the Human T cell Nucleofector Kit. RFX1 and histone methyltransferase suppressor
of variegation 3-9 (Drosophila) homolog 1 (SUV39H1) interaction was determined by co-immunoprecipation (co-IP)
and Western blot and immunofluorescence staining. CD11a and CD70 mRNA levels were measured by real-time
RT-PCR.
Results: H3K9 tri-methylation levels were significantly reduced within the CD11a and CD70 promoter regions in
SLE CD4
+ T cells. RFX1 co-immunoprecipitated with SUV39H1 at the CD11a and CD70 promoters in healthy control
CD4
+ T cells. Overexpressing or knocking-down RFX1 revealed that RFX1 expression correlated with H3K9 tri-
methylation levels, as well as CD11a and CD70 expression levels in CD4
+ T cells.
Conclusions: RFX1 recruits SUV39H1 to the promoter regions of the CD11a and CD70 genes in CD4
+ T cells,
thereby regulating local H3K9 tri-methylation levels. These findings shed further light on the central role of RFX1
down-regulation in the epigenetic de-repression of auto-immune genes in SLE.
Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by excess production of
autoantibodies. Multiple studies have demonstrated the
important role of epigenetic alterations in triggering the
hyper-activation of T lymphocytes that leads to lupus
and lupus-like diseases [1-3]. T-cell autoreactivity in
lupus is thought to be due in part to the overexpression
of adhesion molecule lymphocyte function-associated
antigen 1 (LFA-1, composed of cluster of differentiation
(CD) 11a and CD18 subunits) [4,5], and of CD70
(TNFSF7), which induces B cells to over-produce auto-
antibodies [6,7]. Our previous studies have confirmed
that DNA hypomethylation and histone hyperacetylation
of CD11a and CD70 promoter regions contribute to
their overexpression in SLE CD4
+ Tc e l l s[ 8 - 1 0 ] .H o w -
ever, the mechanisms leading to deregulated epigenetic
modifications at the CD11a and CD70 gene loci are not
completely understood.
The transcription factor regulatory factor X-box 1
(RFX1), the first cloned member of the RFX family, is
down-regulated in CD4
+ T cells of SLE patients [11].
RFX1 contains a C-terminal repressive region, an over-
lapping dimerization domain, and an N-terminal
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any medium, provided the original work is properly cited.activation domain, and is capable of both activating and
repressing target gene transcription [0] depending on
the cellular context [12]. Although the mechanisms by
which RFX1 exerts its activation or repression activity
have only been partially elucidated, it is known that
RFX1 behaves as a potent transcriptional repressor in
CD4
+ T cells [10]. In these cells, RFX1 binds to target
genes, including CD11a and CD70, and recruits the
transcriptional co-repressors histone deacetylase 1
(HDAC1) and DNA methyltransferase1 (DNMT1). This
leads to local histone hypoacetylation and DNA hyper-
methylation and consequently to the suppression of tar-
get gene expression [10]. In a previous study, we found
that RFX1 is significantly down-regulated in SLE CD4
+
T cells. We also demonstrated that RFX1 forms a stable
complex with HDAC1 and DNMT1 in the nucleus of
CD4
+ T cells, and that down-regulating RFX1 in these
cells increases histone acetylation and decreases DNA
methylation at the CD11a andC D 7 0p r o m o t e rr e g i o n s ,
epigenetic changes that lead to the de-repression of
CD11a and CD70 [10].
Another epigenetic mechanism for repressing gene
transcription is the methylation of specific lysine resi-
dues in histones, a modification that is critical to shap-
ing repressive chromatin structures [13,14]. Among the
histone methyltransferases involved in this process, the
best characterized is the suppressor of variegation 3-9
(Drosophila) homolog 1 (SUV39H1). By tri-methylating
lysine 9 in histone H3 (H3K9) SUV39H1 is able to gen-
erate a binding site for the transcriptional repressor het-
erochromatin-associated protein 1 (HP1) [15,16].
Therefore, H3K9 tri-methylation is involved in gene
repression and serves as a marker for the establishment
of a stable heterochromatin configuration [17]. In the
present study, we show that RFX1 binds to CD11a and
CD70 promoter DNA in CD4
+ T cells where it recruits
SUV39H1 and regulates H3K9 tri-methylation levels.
We further reveal that the down-regulation of RFX1 in
SLE CD4
+ T cells reduces local H3K9 tri-methylation
levels around the promoters of CD11a and CD70, thus
further contributing to the de-repression of these critical
auto-immune factors.
Materials and methods
Patients and controls
Patient demographics and treatment regimens are
shown in Table 1. SLE patients (mean age 27 ± 6 yrs)
were recruited from outpatient clinics of the Second
Xiangya Hospital Central South University. All patients
fulfilled at least four of the SLE classification criteria of
the American College of Rheumatology [18]. Lupus dis-
ease activity was assessed using the SLE Disease Activity
Index (SLEDAI) [19]. Healthy controls (mean age 25 ±
3 yrs) were recruited from medical staff at the Second
Xiangya Hospital. This study was approved by the
human ethics committee of the Central South University
Xiangya Medical School, and written informed consent
was obtained from all subjects. Patients and controls
were age- and sex-matched in all experiments.
Isolation, culturing and transfection of T cells
A total of 60 ml of venous peripheral blood was with-
drawn from each patient and control subject and pre-
served with heparin. CD4
+ T cells were isolated by
positive selection using CD4 beads, according to proto-
cols provided by the manufacturer (Miltenyi, Bergisch
Gladbach, Germany; purity was generally higher than
95%), and cultured in human T cell culture medium
( L o n z a ,W a l k e r s v i l l e ,M D ,U S A ) .C D 4
+ Tc e l l sw e r e
transfected with plasmids using the Human T cell
Nucleofector Kit and Amaxa nucleofector (Lonza). In
brief, CD4
+ T cells were harvested and resuspended in
100 μl human T cell nucleofector solution. The cell sus-
pension was then mixed with 10 μg empty plasmids
(pSUPER or pSG5) or plasmid vectors encoding an
RFX1-targeting siRNA (pSuper.RFX1) or full-length
RFX1 cDNA (pSG5-RFX1, both provided by Dr. Yosef
Shaul, Weizmann Institute of Science, Rehovot, Israel).
The mix was electrotransfected using the nucleofector
program V-024 in the Amaxa nucleofector. Transfected
cells were cultured in human T cell culture medium
and harvested 48 hours later.
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed according to the instruc-
tions provided with the ChIP assay kit (Millipore, Biller-
ica, MA, USA). In brief, CD4
+ T cells were fixed for eight
minutes at RT with 1% formaldehyde. Glycine was then
Table 1 Patient demographics and medications
Patient SLEDAI score Medications
1 14 None
2 14 None
3 14 Pred15mg/d
4 10 Pred 10 mg/d
5 14 None
6 14 None
7 19 Pred 20 mg/d
8 15 Pred 30 mg/d
9 14 Pred 10 mg/d
10 24 Pred 20 mg/d
11 16 Pred 5 mg/d
12 20 None
13 18 Pred 15 mg/d
14 20 Pred 2.5 mg/d
15 14 Tria 8 mg/d
Pred, Prednisone; SLEDAI, Systemic Lupus Erythematosus Disease Activity
Index; Tria, Triamcinolone.
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formaldehyde. Cells were pelleted, washed once with ice-
cold PBS, and lysed. Lysates were pelleted, resuspended,
and sonicated to reduce DNA to 500 to 1,000 base pair
fragments. Chromatin was precipitated with protein A
agarose beads for one hour and then incubated with tri-
methylated H3K9 antibody (Abcam, Cambridge, MA,
USA) or control rabbit IgG (Millipore) overnight. The
immunocomplexes were precipitated once again with
protein A agarose beads, washed, and eluted in 100 ml of
TE with 0.5% SDS and 200 mg/ml proteinase K. Precipi-
tated DNA was further purified with phenol/chloroform
extranction and ethanol before amplifying target DNA by
reverse transcriptase-polymerase chain reaction
(RT-PCR). Primers used were as follows: CD11a, 5’-
CAGCCTGTTGCCTCTGTGAGA-3’ (forward) and
5’-GGCAGCT CCTTGTTTACTCC-3’ (reverse);
and CD70, 5’-GGGCGTCTACTTGCTTCA-3’ (forward)
and 5’-CCTGCATCCTGGCAACTGC-3’ (reverse).
Real-time quantitative polymerase chain reaction (qPCR)
qPCR was used to quantify the abundance of DNA frag-
ments of CD11a and CD70 promoter DNA fragments.
These experiments were performed with 20 μl reaction
volumes containing 10 μl2 × S Y B R
® Premix Ex Taq
(TaKaRa Biotech (Dalian) Co., Dalian, China), 0.4 μMo f
each primer, 1 μl of cDNA template, and 8.2 μl deionized
water. PCR amplifications were done in a Rotor-Gene3000
(Corbett Research, Mortlake, NSW, Australia) using the fol-
lowing parameters: 95°C for 10 s, 40 cycles through 95°C
for 5 s, 58°C to 60°C for 31 s. Melting curve analysis (from
65°C to 95°C, followed by cooling to 40°C) was also per-
formed to exclude non-specific PCR products. All PCR pro-
ducts were checked by melting curve analysis to exclude the
possibility of multiple products or incorrect product size.
PCR analyses were conducted in triplicate for each sample.
RNA isolation and real-time quantitative RT-PCR
Total RNA was isolated from CD4
+ T cells using the
RNeasy mini kit (Qiagen, Valencia, CA, USA). Real-time
quantitative RT-PCR was performed using a Rotor-
Gene3000 (Corbett Research) and mRNA levels were
quantified using the One Step PrimeScript RT-PCR Kit
(TaKaRa Biotech (Dalian) Co). A dilution series of sam-
ple RNA was also included to generate a standard curve
used to calculate relative concentrations of transcript in
each RNA sample. b-actin was also amplified and used as
a loading control. Primers used were as follows: CD11a,
5’-TGAGAGCAGGCTATTT GGGTTAC-3’ (forward)
and 5’-CGGCCCATGTGCTGGTAT-3’ (reverse); CD70,
5’- CACACTCTGCACCTCACT-3’ (forward) and
5’-CACCCACTGCACTCCAAAGA-3’ (reverse); and
b-actin, 5’-CGCGAGAAGATGACCCAGAT-3’ (forward)
and 5’-GCAC TGTGTTGGCGTACAGG-3’ (reverse).
Western blots
Western blots were performed as described previously
[20]. Primary antibodies used included: anti-SUV39H1
(1:1000; Santa Cruz Biotechnology, CA, USA), anti-
RFX1 (1:100; Santa Cruz Biotechnology) Blots were
visualized using SuperSignal West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL, USA) and exposed
to X-ray films. Band densities were quantified using
Quantity One software (Bio-Rad, Hercules, CA, USA).
Co-immunoprecipitation (co-IP)
Whole CD4
+ T cell lysates were obtained by resuspend-
ing CD4
+ T cell pellets in RIPA buffer. Lysates were
incubated overnight with RFX1 antibody (Santa Cruz
Biotechnology) before being absorbing with protein A/G
PLUS-agarose beads (Millipore). Precipitated immuno-
complexes were released by boiling with 2 × SDS elec-
trophoresis sample buffer and prepared for western blot
analysis.
Immunofluorescence analysis
Fixed and permeabilized cells were incubated with anti-
RFX1 (1:100; Santa Cruz Biotechnology), anti-SUV39H1
(1:200; Santa Cruz Biotechnology) and anti-Bcl-2 (1:100;
Santa Cruz Biotechnology) antibodies, followed by
FITC- and TRITC-conjugated secondary antibodies
(Santa Cruz Biotechnology) using standard procedures.
Nuclei were counter-stained with DAPI (Santa Cruz
Biotechnology). Images were captured using a Zeiss
LSM5 confocal microscope (Carl Zeiss, Thornwood, NY,
USA).
Statistical analysis
Results are expressed as mean ± SD. Data were analyzed
by ANOVA followed by the unpaired Student’s t-test for
multiple comparisons. All analyses were preformed with
SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Sig-
nificance was set as P ≤ 0.05.
Results
The H3K9 tri-methylation levels at the CD11a and CD70
promoters in SLE CD4
+ T cells
Our group previously showed that global H3K9 is
globally hypomethylated in active and inactive lupus
CD4
+ T cells [21]. To investigate the effect of aberrant
histone methylation on the expression of the auto-
immune related genes CD11a and CD70, we analyzed
H3K9 tri-methylation levels at the CD11a and CD70
genomic loci in CD4
+ T cells from SLE patients and
healthy controls (n = 15 per group). ChIP-qPCR analy-
sis revealed that the H3K9 in the promoter regions of
CD11a and CD70 are significantly hypomethylated in
SLE CD4
+ T cells compared with control CD4
+ T cells
(Figure 1).
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promoters in CD4
+ T cells
In mammals, H3K9 tri-methylation is primarily, if not
exclusively, due to the action of SUV39H1 [22]. We,
therefore, examined SUV39H1 expression in SLE CD4
+
T cells. As shown in Figure 2, we found that SUV39H1
protein levels do not differ significantly between CD4
+
T cells from SLE patients and healthy controls.
We have previously demonstrated that the transcrip-
tion factor RFX1 recruits the chromatin-modifying
enzymes HDAC1 and DNMT1 to the promoter regions
of CD11a and CD70 in CD4
+ T cells [10]. To determine
whether RFX1 can associate with SUV39H1 and regulate
H3K9 tri-methylation at CD11a and CD70 promoters,
we performed co-IP and Western blot analyses of CD4
+
T cell lysates. SUV39H1 and RFX1 were found to
physically interact in lysates from healthy subjects
(Figure 3a). In contrast, G9a, another histone methyl-
transferase, did not co-IP with RFX1 (Figure 3a), sug-
gesting that RFX1 binds specifically to SUV39H1.
Furthermore, co-immunolabeling confirmed that
SUV39H1 and RFX1 proteins co-localize in the nucleus
of CD4
+ T cells (Figure 3b). We then used a ChIP assay
to determine whether SUV39H1 was also recruited to
CD11a and CD70 promoter regions. Figure 3c shows
that SUV39H1 can bind to DNA fragments of the endo-
genous CD11a and CD70 promoter regions from
healthy control CD4
+ T cells.
RFX1 down-regulation causes overexpression of CD11a
and CD70 by reducing promoter H3K9 tri-methylation
levels
To assess whether RFX1 is involved in regulating
H3K9 tri-methylation levels at the CD11a and CD70
promoter loci, we knocked-down RFX1 expression in
healthy CD4
+ T cells by transfecting with an RFX1-
siRNA expression vector, pSUPER.RFX1. Compared
with cells transfected with empty pSUPER vector
(negative control), RFX1 protein levels were decreased
by approximately 90% 48 hours after pSUPER.RFX1
transfection (Figure 4a). We then used qPCR to mea-
sure the levels of CD11a and CD70 promoter DNA
fragments after immunoprecipitating histone-DNA
complexes with anti-tri-methylated H3K9 antibody.
Significantly less CD11a and CD70 promoter DNA was
amplified in pSUPER.RFX1-transfected CD4
+ Tc e l l s
compared with negative controls, indicating a
significant reduction in H3K9 tri-methylation levels
(Figure 4b). In addition, CD11a and CD70 mRNA
expression was significantly up-regulated compared
with negative controls (Figure 4c).
RFX1 overexpression up-regulates H3K9 tri-methylation at
the CD11a and CD70 promoter loci
We have previously shown that RFX1 overexpression
can increase DNA methylation and decrease histone
acetylation levels at the CD11a and CD70 promoters,
leading to reduced CD11a and CD70 expression in
SLE CD4
+ T cells [10]. In this study, we asked
whether overexpressing RFX1 could restore the aber-
rant histone tri-methylation status of SLE CD4
+
T cells. Figure 5a shows a significant increase in RFX1
protein levels in SLE CD4
+ T cells transfected with
the RFX1 expression vector pSG5-RFX1. CD11a and
CD70 promoter H3K9 tri-methylation levels were
significantly higher in RFX1-overexpressing SLE CD4
+
T cells compared to control-transfected SLE CD4
+
T cells (Figure 5b), and this change correlated with a
Figure 1 H3K9 tri-methylation levels in the CD11a (a) and CD70 (b) promoters regions of SLE and healthy control CD4
+ T cells
detected by ChIP and PCR (*, P < 0.01; **, P < 0.05).
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(Figure 5c).
Discussion
CD11a and CD70 are both overexpressed in CD4
+ T cells
of lupus patients, and the degree of overexpression is
directly proportional to disease activity [7]. CD11a over-
expression contributes to autoreactive responses [8],
while CD70 overexpression leads to overstimulation of
IgG synthesis in B cells [9]. The expression of both genes
is also increased in T cells treated with the methylation
inhibitor 5-azacitidine, suggesting that DNA methylation
is involved in regulating the expression of these genes
[7,8]. Our previous studies have confirmed that the pro-
moters of CD11a and CD70 genes are hypomethylation
in SLE CD4
+ T cells, and that this contributes to their
overexpression [7-9,23]. Our group has evidence suggest-
ing that histone acetylation levels at the CD11a and
CD70 promoter loci are higher in SLE CD4
+ T cells than
in healthy controls (Lu Q, unpublished data). These find-
ings demonstrate that changes in epigenetic regulatory
factors lead to the up-regulation of CD11a and CD70
expression in CD4
+ T cells of SLE patients.
H3K9 methylation is one of the most prevalent and
stable histone modifications, and is involved in both
gene repression and heterochromatin formation. In
mammals, heterochromatic regions are highly tri-methy-
lated on H3K9, whereas euchromatin regions are
enriched with mono- and di-methylated H3K9 [24]. Pre-
vious reports have shown that H3K9 tri-methylation
acts as an epigenetic marker of transcriptional suppres-
sion, and the disruption of normal H3K9 tri-methylation
levels is linked to a number of diseases. Increased H3K9
tri-methylation levels are associated with the silencing of
tumor suppressor genes such as P16, P14, MLH1 and
MGMT in cancer cells [25,26]. In contrast, H3K9 tri-
methylation levels are significantly decreased at the pro-
moters of key inflammatory genes IL-6, MCSF and
MCP-1 promoters in vascular smooth muscle cells of
mice with a type 2 diabetes-like condition [27]. In the
present study, we found that H3K9 tri-methylation
levels within the CD11a and CD70 promoter regions
Figure 2 SUV39H1 protein levels from SLE patients (n = 15) and healthy controls (n = 15) measured by Western blot. (a) Representative
blots of SUV39H1 and b-actin (loading control) in SLE patient and healthy control CD4
+ T cells (n = 4 per group). (b) Quantitative analysis of
SUV39H1 band intensities normalized to b-actin (#, P > 0.05).
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Jurkat cells (top) and healthy CD4
+ T cells (bottom) lysates following immunoprecipitation with the antibodies indicated at the top. (b) CD4
+ T
cells from healthy controls co-immunolabeled with anti-RFX1 (green) and anti-SUV39H1 (red). DAPI (blue) was used to label cell nuclei. Merged
images are also shown. Anti-Bcl-2 antibody was included as control to cytoplasm of CD4
+ T cells (green). Scale bar, 10 μm. (c) Anti-SUV39H1
ChIP assay of CD4
+ T cell lysates. CD11a and CD70 promoters were identified by PCR amplification of the DNA fragments precipitated with
SUV39H1 antibody.
Figure 4 CD4
+ T cells after transfection with the RFX1-siRNA expression vector pSUPER.RFX1 or pSUPER (negative control). (a) Anti-
RFX1 western blot of lysates from transfected CD4
+ T cells. Anti-b-actin Western blot is included as a loading control. (b) H3K9 tri-methylation
levels at the CD11a and CD70 promoters in pSUPER.RFX1-transfected CD4
+ T cells relative to pSUPER-transfected cells (*, P < 0.01). C: CD11a and
CD70 mRNA levels in pSUPER.RFX1-transfected CD4
+ T cells relative to pSUPER-transfected cells (*, P < 0.01). Data represent the mean ± SD of
three independent experiments per group.
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+ T cells compared with
healthy controls, consistent with the global H3K9 hypo-
methylation of T cells from SLE patients that we
reported previously [21]. Together, these findings sug-
gest that decreased H3K9 tri-methylation levels is one
of the mechanisms by which CD11a and CD70 expres-
sion becomes up-regulated in SLE CD4
+ T cells.
Many H3K9-specific histone methyltransferases
(HMTs) have been characterized, all of which contain a
conserved Su(var)3-9, Enhancer-of-zeste, Trithorax
(SET) domain [13]. The most well described H3K9 HMT
are the tri-methylase Suv39H1 and 2/KMT1A and -1B,
which contribute mainly to the establishment of peri-
centric heterochromatin [22,28]. Our results showed that
levels of SUV39H1 protein were not significantly differ-
ent between SLE CD4
+ T cells and healthy controls, con-
sistent with the mRNA levels detected by real-time PCR
reported in our previous study [21]. Interestingly, our
ChIP experiments demonstr a t e dt h a tS U V 3 9 H 1c o u l d
bind to the promoter region of CD11a and CD70, sug-
gesting that decreased tri-methylation at these promoters
could potentially be associated with a reduction of
SUV39H1 activity within these chromosomal regions.
Studies have shown that SUV39H1 can be recruited
by transcription factors to the promoter region of speci-
fic genes where it then regulates histone methylation
levels locally, and thereby represses target gene expres-
sion [29,30]. In a previous study, we screened SLE CD4
+
T cells for differential transcription factor activity using
a microarray-based technique. Among our results, we
found that RFX1 is significantly down-regulated in SLE
patient T cells and also demonstrated that reduced
RFX1 expression leads to the de-repression of CD11a
and CD70 in SLE CD4
+ T cells. This was found to be
due to the reduction of HDAC1 and DNMT1
recruitment, which in turn leads to an increase of his-
tone acetylation and a decrease in DNA methylation
within CD11a and CD70 promoter regions [10]. In the
present study we found that SUV39H1 could directly
interact with RFX1 and the two molecules co-localized
in the nucleus of CD4
+ T cells. Furthermore, we found
that RFX1 levels directly correlated with H3K9 tri-
methylation levels. Knocking-down RFX1 in healthy
control CD4
+ T cells reduced the level of H3K9 tri-
methylation at the CD11a and CD70 promoters,
whereas overexpressing RFX1 in SLE CD4
+ T cells had
the opposite effect. Thus, we infer that decreased H3K9
tri-methylation in SLE CD4
+ T cells is partly due to the
reduction in RFX1 protein levels.
Taken together, our previous studies and the present
findings suggest that RFX1 restricts the expression of
CD11a and CD70 and possibly other autoimmune-
related genes by maintaining a repressive chromatin
state of their promoters. The down-regulation of RFX1
CD4
+ T cells in patients with SLE contributes to, and
perhaps triggers, the decondensation of chromatin
around the CD11a and CD70 gene loci by disrupting
the normal regulation of epigenetic modifications in
these regions. This leads to the CD11a and CD70 over-
expression and the onset of T-cell auto-reactivity [10].
Our findings provide new evidence of the key role of
transcription factors in regulating the chromatin status
of their target genes.
Conclusions
In summary, our data further support a model whereby
the binding of RFX1 to specific regulatory regions in
healthy CD4
+ T cells leads to the recruitment of
SUV39H1, HDAC1 and DNMT1 core complexes, which
together inhibit the expression of RFX1 target genes.
Figure 5 SLE CD4
+ T cells after transfection with RFX1 expression vector pSG5-RFX1, or with pSG5 (negative control). (a) Anti-RFX1
western blot of lysates from transfected CD4
+ T cells. Anti-b-actin western blot is included as a loading control. (b) H3K9 tri-methylation levels
at the CD11a and CD70 promoters in pSG5-RFX1-transfected CD4
+ T cells relative to pSG5-transfected cells (*, P < 0.01; **, P < 0.05). (c) CD11a
and CD70 mRNA levels in pSG5-RFX1-transfected CD4
+ T cells relative to pSG5-transfected cells (*, P < 0.01; **, P < 0.05). Data represent the
mean ± SD of three independent experiments per group.
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+ T cells of patients with SLE, the com-
bined activity of these RFX1-dependent transcriptional
repressor complexes is insufficient due to the down-regu-
lation of RFX1, thus leading to the de-repression of auto-
immune related target genes, such as CD11a and CD70.
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